The Investigation on Nosocomial Infection of Acinetobacter baumannii and the Clinical Analysis of Sequential Therapy of Cefoperazone/Sulbactam Sodium for Intracranial Infection

Zezhong Xiong, Defu Zeng, Shilong Shen, and Zhibang Han

Intensive Care Unit Part 1, Qinzhou Second People’s Hospital, Guangxi, Qinzhou 535000, China

Correspondence should be addressed to Zezhong Xiong; 2016123987@jou.edu.cn

Received 20 June 2022; Revised 4 July 2022; Accepted 11 July 2022; Published 16 August 2022

1. Introduction

As one of the common serious complications after neurosurgery, intracranial infection can make the patient’s condition complicated. The incidence of intracranial infection is about 2.2%-2.6%, which directly affects the disease outcome and prognosis of patients and even leads to death. With strong clonal transmission ability and susceptibility to drug resistance, Acinetobacter baumannii becomes a common pathogen causing intracranial infection. And the risk factors causing intracranial infection with Acinetobacter baumannii have been discussed clinically [1]. Active anti-infective therapy is the first choice for intracranial infection; however, the anti-infective treatment of intracranial infection requires not only...
strong killing effect on pathogens but also the ability to penetrate the blood-brain barrier and achieve high drug concentration locally [2].

Tigecycline, the glycylcycline antibiotic, is a commonly used therapeutic drug for intracranial infection caused by Acinetobacter baumannii. However, due to the current situation of bacterial resistance, a considerable number of patients are still cured ineffectively after tigecycline treatment [3]. Cefoperazone/sulbactam sodium is a compound preparation composed of cephalosporin antibiotics and sulbactam sodium, and sulbactam can protect the antibacterial effect of cefoperazone by inhibiting the activity of β-lactamase [4]. In order to better solve the problem of postoperative infection in neurosurgery, this study analyzed the risk factors for postoperative intracranial infection of Acinetobacter baumannii to help clinically avoid risks and observed the clinical effect of sequential treatment of cefoperazone sulbactam sodium to provide a reference for clinical medication. The relevant reports are as follows.

1.1. Core Tips. Due to the great harmfulness of intracranial infection caused by Acinetobacter baumannii after surgery, the effect of tigecycline therapy remains unsatisfactory. This study found that the risk factors for intracranial infection caused by Acinetobacter baumannii after surgery included increasing age of patients, surgical treatment for intracranial tumor or craniocerebral trauma, postoperative drainage time (≥3 days) and postoperative hospital stay (≥10 days), and postoperative prophylactic antibiotic treatment could reduce the incidence of intracranial infection, so more attention should be paid to avoiding risks in future clinical work. And the clinical effect of sequential therapy of tigecycline combined with cefoperazone/sulbactam sodium was better than that with tigecycline alone.

2. Materials and Methods

2.1. General Information. In this case-control study, 48 patients with intracranial Acinetobacter baumannii infection after neurosurgery in our hospital from January 2016 to December 2021 were selected as the infection group, and 96 patients without intracranial infection after surgery during the same period were selected as the control group.

Inclusion criteria include (1) having a history of craniocerebral surgery, (2) being 18–75 years old, and (3) the main clinical manifestations of the patients being at least 2 of the following 5 points: headache, fever, nausea, vomiting, and meningeal irritation. The request of the expert group was signed by all the participants. Exclusion criteria include (1) other types of infection, (2) previous history of viral meningitis, (3) persons with mental illness, and (4) a history of craniotomy or craniocerebral trauma.

2.2. Treatment Methods. The patients in the tigecycline group were treated with tigecycline (Pfizer Pharmaceutical Co., Ltd., manufacturer name: WyEthan Lederle Sr.L., specification: 50 mg, approved by Chinese medicine HJ20160471), while the patients in the combined group were treated with sequential therapy of tigecycline combined with cefoperazone/sulbactam sodium (the trade name is “Supushin,” Pfizer Pharmaceutical Co., Ltd., specification: 3.0 g, approved by Chinese medicine H10960113), and the dosage of tigecycline in this group was the same as that in the control group. Intravenous infusion of cefoperazone/sulbactam sodium was injected 2 times a day, 3.0 g each time. Both groups were treated for 4 consecutive weeks to evaluate the curative effect.

2.3. Observation Indexes and Detection Methods. The white blood cells (WBC) in cerebrospinal fluid, the count of nucleated cells in cerebrospinal fluid, procalcitonin (PCT) in cerebrospinal fluid, and serum C-reactive protein (CRP) in the two groups of patients before and after treatment were detected and compared. By analyzing the clinical application of antibiotics for inpatients in neurosurgery [5], the treatment effect was divided into three outcomes: cured (after treatment, the patients’ clinical symptoms and signs completely disappeared), the laboratory indexes became normal, and bacteriological examination were confirmed negative), effective (the clinical symptoms, signs, and laboratory indexes of patients were better, one of which was not up to the standard, and bacteriological examination was confirmed negative), and ineffective (72 hours after treatment, patients did not get better).

Before treatment and 72 hours after treatment, 3 mL of cerebrospinal fluid was extracted from the patient to be detected by a microscope for WBC, the rest of which was centrifuged at 2500 r/min for 10 minutes. The supernatant was collected to detect the sugar content and the nucleated cell count in the cerebrospinal fluid. The reagent kit used in this study was made by the Beijing North Institute of Biotechnology, and the detection instrument used in the study was a microplate reader (Shenzhen Mindray Medical Electronics Co., Ltd., RT-96A). Before treatment and 72 hours after treatment, 2 mL of peripheral venous blood was drawn from patients as samples to be centrifuged at 3000 r/min for 10 minutes in a centrifuge. After that, the serum was collected to detect CRP and PCT. The reagent kit used in this study was made by the Beijing North Institute of Biotechnology, and the detection instrument used in the study was a microplate reader (Shenzhen Mindray Medical Electronics Co., Ltd., RT-96A).

2.4. Statistical Processing. In this study, the patients’ WBC, CSF counts of nucleated cells, serum CRP, serum PCT, and other measurement indexes were examined by normal distribution, all of which were in line with approximately normal distribution or normal distribution and were expressed as \( \bar{x} \pm s \). In the study, the \( T \)-test was used to compare the two groups; the \( \chi^2 \) test was used for the comparison of count data between groups; the logistic regression model was adopted for the multivariate model, and the enter method was used for variable selection; the data was processed by professional SPSS21.0 software with the test standard of \( \alpha = 0.05 \).

3. Results

3.1. Univariate Analysis. The univariate method was used to analyze the differences in age, BMI, operation time, gender, and other indexes between the infection group and the
control group. The results showed that the age, prevalence rate of chronic obstructive pulmonary disease, the number of intracranial tumor, the number of craniocerebral trauma, postoperative drainage time (≥3 days), and postoperative hospital stay (≥10 days) in the infection group were significantly more than those in the control group. The proportion of patients with prophylactic use of antibiotics in the infection group was lower than that in the control group, and the difference was statistically significant (P < 0.05).

See Table 1 for more details.

3.2. Multivariate Analysis. This study took the occurrence of intracranial Acinetobacter baumannii infection as the dependent variable and took the statistically significant indexes including age, prevalence rate of chronic obstructive pulmonary disease, the number of intracranial tumor, the number of traumatic brain injury, postoperative drainage time, postoperative hospital stay, and prophylactic use of antibiotics as independent variables through the univariate analysis to establish a logistic regression factor model. And the results showed that increasing age of patients, surgical treatment for intracranial tumor or craniocerebral trauma, postoperative drainage time (≥3 days), and postoperative hospital stay (≥10 days) were the risk factors for postoperative intracranial infection of Acinetobacter baumannii in neurosurgical patients (P < 0.05), and postoperative prophylactic antibiotic treatment can reduce the incidence of intracranial infection (P < 0.05). See Table 2 for more details.

3.3. Comparison of Laboratory Indexes before and after Treatment in Patients with Intracranial Infection. By detecting the laboratory indexes of the tigecycline group and the combination group before treatment and 72 hours after treatment, the number of nuclear cells in cerebrospinal fluid and serum CRP and PCT levels in the combination group after 72 hours of treatment were lower than those in the tigecycline group; the differences were statistically significant (P < 0.05). See Table 3.

3.4. Comparison of Clinical Efficacy. 72 hours after treatment, clinical curative effect comparison found in the combined treatment group of patients with cure rate was 83.33%, the effective rate was 16.67%, the treatment of

| Table 1: Univariate analysis results. |
|--------------------------------------|
| Normal information                  | Infection group (n = 48) | Control group (n = 96) | t/χ² | P       |
| Age (years)                          | 66.4 ± 7.1               | 63.1 ± 6.8             | 2.705 | 0.008   |
| BMI (kg/m²)                          | 23.41 ± 1.55             | 23.28 ± 1.67           | 0.451 | 0.653   |
| Operation time (min)                 | 174.2 ± 22.5             | 170.7 ± 23.2           | 0.862 | 0.390   |
| Gender (%)                           |                          |                       | 0.508 | 0.476   |
| Male                                 | 29 (60.42)               | 52 (54.17)             |       |         |
| Female                               | 19 (39.58)               | 44 (45.83)             |       |         |
| Concomitant disease (%)              |                          |                       |       |         |
| Hypertension                         | 23 (47.92)               | 35 (36.46)             | 1.747 | 0.186   |
| Diabetes                             | 16 (33.33)               | 23 (23.96)             | 1.424 | 0.233   |
| Coronary heart disease               | 6 (12.5)                 | 8 (8.33)               | 0.633 | 0.426   |
| Chronic obstructive pulmonary disease| 15 (31.25)               | 14 (14.58)             | 5.527 | 0.019   |
| Type of neurological disease (%)     |                          |                       |       |         |
| Hypertensive intracerebral hemorrhage| 11 (22.92)               | 34 (35.42)             | 2.327 | 0.127   |
| Cerebral infarction                  | 14 (29.17)               | 40 (41.67)             | 2.133 | 0.144   |
| Intracranial tumor                   | 12 (25)                  | 7 (7.29)               | 8.761 | 0.003   |
| Traumatic brain injury               | 8 (16.67)                | 5 (5.21)               | 5.116 | 0.024   |
| Other                                | 3 (6.25)                 | 8 (8.33)               | 0.699 | 0.403   |
| Prophylactic use of antibiotics (%)  |                          |                       |       |         |
| Yes                                  | 40 (83.33)               | 91 (94.79)             | 5.116 | 0.024   |
| No                                   | 8 (16.67)                | 5 (5.21)               |       |         |
| Postoperative blood transfusion (%)  |                          |                       | 0.924 | 0.336   |
| Yes                                  | 22 (45.83)               | 36 (37.5)              |       |         |
| No                                   | 26 (54.17)               | 60 (62.5)              |       |         |
| Postoperative drainage time (%)      |                          |                       | 12.382| 0.000   |
| ≥3 d                                 | 25 (52.08)               | 22 (22.92)             |       |         |
| <3 d                                 | 23 (47.92)               | 74 (77.08)             |       |         |
| Postoperative hospital stay (%)      |                          |                       | 8.533 | 0.003   |
| ≥10 d                                | 38 (79.17)               | 52 (54.17)             |       |         |
| <10 d                                | 10 (20.83)               | 44 (45.83)             |       |         |
patients with the tigecycline group was 54.17%, their effective rate was 33.33%, and the invalid rate was 12.50%. On this basis, the combination group was better than the tigecycline group (P < 0.05). See Table 4.

### 4. Discussion

The scope of intracranial infection involves brain tissue, spinal cord, and adjacent tissues. Certain studies showed that the intracranial infection rate after neurosurgery was 3.26%-9.40%, which was related to the destruction of the blood-brain barrier [6]. Postoperative opening central nervous system and cerebrospinal fluid circulation system, catheter drainage, tracheotomy, tracheal intubation, nasal feeding, and other factors will increase the risk of intracranial infection, and postoperative bloody cerebrospinal fluid is a good medium for bacterial reproduction [7]. Acinetobacter baumannii, a gram-negative bacillus, is not only a human conditional pathogenic bacteria but also a common pathogen that causes intracranial infections [8]. Most antibiotics cannot pass the blood-brain barrier, which results in difficulty and poor clinical efficacy in the treatment of intracranial infections [9]. The logistic regression factor model results in this study showed that increasing age of patients, surgical treatment for intracranial tumor or craniocerebral trauma, postoperative drainage time (≥3 days), and postoperative hospital stay (≥10 days) were the risk factors for postoperative intracranial infection of Acinetobacter baumannii in neurosurgical patients, and postoperative prophylactic antibiotic treatment can reduce the incidence of intracranial infection. In future clinical work, elderly patients, patients undergoing surgery due to intracranial tumor or traumatic brain injury, and patients with long postoperative drainage time and postoperative hospital stay should be regarded as high-risk groups of intracranial infection, and antibiotics should be used preventively before surgery to reduce the risk of infection.

Tigecycline, the glycylcycline antibiotics, has bacteriostatic effect on multidrug-resistant bacteria such as carbapenem-resistant Acinetobacter and Klebsiella pneumoniae, and its binding ability to bacterial ribosomes is stronger than that of other tetracycline antibiotics, so it is often used clinically in the treatment of complex skin and soft tissue infections, intra-abdominal infections, acquired pneumonia, and other diseases in adults [10]. Many studies showed that tigecycline had positive in vitro antibacterial activity against resistant Acinetobacter baumannii, but sole use of it may lead to resistant bacteria [11, 12]. Cefoperazone sulbactam sodium, the broad-spectrum antibiotic, has a certain therapeutic effect on respiratory tract infections, urogenital infections, intra-abdominal infections, bone and joint infections, intracranial infections, and skin and soft tissue infections caused by sensitive bacteria [13, 14].

In this study, it was found that the efficacy of sequential therapy of tigecycline combined with cefoperazone/sulbactam sodium was better than that of therapy of tigecycline alone. Immune response after intracranial infection will lead to higher WBC levels in blood and infected parts to remove pathogens, and the levels of WBC in cerebrospinal fluid after the destruction of the blood-brain barrier will also be higher [15]. After intracranial infection, the body’s immune

### Table 2: Logistic multivariate analysis results.

| Index                                | β    | SE   | Walds | P     | OR   | 95% CI        |
|--------------------------------------|------|------|-------|-------|------|---------------|
| Age                                  | 0.604| 0.301| 4.027 | 0.049 | 1.829| 1.014 - 3.300 |
| Chronic obstructive pulmonary disease| 0.587| 0.314| 3.495 | 0.091 | 1.799| 0.972 - 3.328 |
| Type of neurological disease         | 0.718| 0.327| 4.821 | 0.041 | 2.050| 1.080 - 3.892 |
| Prophylactic use of antibiotics      | 0.594| 0.264| 5.063 | 0.038 | 1.811| 1.080 - 3.039 |
| Postoperative drainage time          | 0.773| 0.328| 5.554 | 0.031 | 2.166| 1.139 - 4.120 |
| Postoperative hospital stay          | 0.695| 0.314| 4.899 | 0.047 | 2.004| 1.083 - 3.708 |
| Constant term                        | 1.103| 0.627| 3.095 | 0.058 | 3.013| 0.882 - 10.298|

### Table 3: Comparison of laboratory indexes before and after treatment in patients with intracranial infection (x ± s).

| Group               | n   | CSF WBC (10^6/L) Before therapy | Treatment 72 h | Serum CRP (mg/L) Before therapy | Treatment 72 h | Serum PCT (μg/L) Before therapy | Treatment 72 h |
|---------------------|-----|---------------------------------|----------------|---------------------------------|----------------|---------------------------------|----------------|
| Tigecycline group    | 24  | 11.83 ± 1.95                    | 8.11 ± 1.40    | 19.50 ± 4.41                    | 7.52 ± 2.04    | 2.74 ± 0.77                      | 0.41 ± 0.12    |
| Joint group          | 24  | 11.55 ± 2.01                    | 6.63 ± 1.63    | 21.07 ± 5.28                    | 5.26 ± 1.83    | 2.68 ± 0.78                      | 0.30 ± 0.10    |
| t                   | 0.49| 2.918                           | -1.118         | 4.04                            | 0.268          | 3.45                            |
| P                   | 0.627| 0.005                           | 0.269          | 0                               | 0.79           | 0.001                           |

### Table 4: Comparison of clinical efficacy (n (%)).

| Group               | n   | Cure  | In force | Invalid |
|---------------------|-----|-------|----------|---------|
| Tigecycline group    | 24  | 13 (54.17)| 8 (33.33)| 3 (12.50)|
| Combined group       | 24  | 20 (83.33)| 4 (16.67)| 0 (0.00)|
| Z                   | -2.285|
| P                   | 0.022|
response leads to an increase in the level of WBC in the blood and local infection to eliminate pathogens, and the level of WBC in the cerebrospinal fluid and the count of nucleated cells in the cerebrospinal fluid increase after the breakdown of the blood-brain barrier [16]. Immune response after intracranial infection leads to elevated levels of blood and infected local nucleated cells (white blood cells, lymphocytes, and monocytes) to remove pathogens and increased cerebrospinal fluid nucleated cell count after blood-brain barrier damage. Cerebrospinal fluid lactate is a by-product of bacterial metabolism, whose level will not be influenced by blood lactate levels but will increase sharply after intracranial bacterial infection [17]. CRP and PCT are important diagnostic indexes and disease evaluation indexes in the early stage of bacterial infection, which can be higher in the early stage of infection. This study showed that the number of nuclear cells in cerebrospinal fluid, serum CRP, and serum PCT levels in patients treated with tigecycline combined with cefoperazone combined with sulbactam sodium after 72 hours were lower than those in patients treated with tigecycline alone [18]. This study showed that 72 hours after tigecycline combined with cefoperazone and sulbactam sodium treatment, cerebrospinal fluid WBC, cerebrospinal fluid nucleated cell count, serum CRP, and serum PCT levels were lower than those in the tigecycline alone group. The above results suggest that the sequential therapy of tigecycline combined with cefoperazone/sulbactam sodium can better control intracranial infection in patients with intracranial Acinetobacter baumannii infection. This is because tigecycline can play an antibacterial role by binding to the 30S subunit of bacterial ribosome and inhibiting bacterial protein synthesis [19], and cefoperazone can exert its antibacterial effect by inhibiting bacterial cell wall synthesis. Although sulbactam sodium itself has no antibacterial effect, it has an irreversible inhibitory effect on the production of β-lactamase by gram-negative bacilli, reducing its effect on the efficacy of cephalosporin antibiotics [20]. In general, the three-drug components can exert synergistic effects through different pathways to better control intracranial infection.

To sum up, patients undergoing craniotomy are in need of targeted preventive intervention for risk factors that may lead to intracranial Acinetobacter baumannii infection; sequential therapy of tigecycline combined with cefoperazone/sulbactam sodium in patients with intracranial Acinetobacter baumannii infection has better clinical efficacy. Compared with previous studies, this study objectively and quantitatively reflected the efficacy of tigecycline combined with cefoperazone/sulbactam sodium in the sequential treatment of intracranial Acinetobacter baumannii infection by detecting the number of nucleated cells in cerebrospinal fluid, serum CRP, serum PCT, and other indicators at 72 h after treatment, providing a reference for clinical medication. However, since only 48 patients with infection after craniotomy were selected in this study, the sample size after grouping was only 24 cases, which may have a certain bias on the results; more sample size should be accumulated to further explore the effect of tigecycline combined with cefoperazone sulbactam sodium in the sequential treatment of intracranial Acinetobacter baumannii infection.

**Data Availability**

The datasets used and analyzed during the current study are available from the corresponding author upon reasonable request.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**References**

[1] S. M. Cho, T. Lee, R. C. Starling, N. R. Thompson, and K. Uchino, “The impact of infection and elevated INR in LVAD-associated intracranial hemorrhage: a case-crossover study,” *ASAIO Journal*, vol. 65, no. 6, pp. 545–549, 2019.

[2] B. Kim, K. Kim, and J. S. Yoon, "Nosocomial Acinetobacter baumannii infection in children in adult versus pediatric intensive care units," *Pediatrics International*, vol. 62, no. 4, pp. 451–458, 2020.

[3] S. Li, "Network pharmacology evaluation method guidance - draft," *World Journal of Traditional Chinese Medicine*, vol. 7, no. 1, pp. 148–154, 2021.

[4] R. E. Saraya and E. A. Abdel Hameed, "Eco-friendly micellar HPTLC technique for the simultaneous analysis of co-formulated antibiotic cefoperazone and sulbactam in pure form and vial pharmaceutical formulation," *Journal of Planar Chromatography-Modern TLC*, vol. 34, no. 2, pp. 121–129, 2021.

[5] J. Li, Y. Yuan, J. Zhao, W. M. Li, and Z. Chun, “Analysis of clinical use of antibiotics in hospitalized patients in neurosurgery,” *Journal of Xinjiang Medical University*, vol. 42, no. 2, pp. 181–185, 2019.

[6] E. Nagata, T. Nishiyama, M. Yamashita, T. Ishigami, and T. Oho, "A primary canine and an impacted permanent canine with infection potentially induced an intracranial abscess," *Australian Dental Journal*, vol. 65, no. 1, pp. 96–99, 2020.

[7] T. Lee, A. B. Buletko, J. Matthew, and S. M. Cho, "Bloodstream infection is associated with subarachnoid hemorrhage and infectious intracranial aneurysm in left ventricular assist device," *Perfusion*, vol. 35, no. 2, pp. 117–120, 2020.

[8] S. A. Girija, J. V. Priyadharsini, and A. Paramasivam, "Prevalence of carbapenem-hydrolyzing OXA-type beta-lactamasas among Acinetobacter baumannii in patients with severe urinary tract infection," *Acta Microbiologica et Immunologica Hungarica*, vol. 67, no. 1, pp. 49–55, 2020.

[9] R. Ivaturi, T. M. Sastry, and S. Sunkara, “Development and validation of stability indicating HPLC method for the determination of impurities in the sterile mixture of cefoperazone and sulbactam,” *Current Pharmaceutical Analysis*, vol. 15, no. 7, pp. 762–775, 2019.

[10] B. I. Salman, M. F. Ali, M. A. Marzoouq, and S. A. Hussein, “Utility of the fluorogenic characters of benzofurazan for analysis of tigecycline using spectrometric technique; application to pharmacokinetic study, urine and pharmaceutical formulat ions,” *Luminescence*, vol. 34, no. 2, pp. 175–182, 2019.

[11] R. W. Hooper, D. S. Ashcraft, and G. A. Pankey, "In vitro synergy with fluconazole plus doxycycline or tigecycline against clinical Candida glabrata isolates," *Medical Mycology*, vol. 57, no. 1, pp. 122–126, 2019.

[12] B. Curebal, N. Dalgic, and B. Bayraktar, "Intraventricular tigecycline for the treatment of shunt infection: a case in
[13] E. Guclu, G. Kaya, A. Ogutlu, and O. Karabay, “The effect of cefoperazone sulbactam and piperacillin tazobactam on mortality in gram-negative nosocomial infections,” *Journal of Neurosurgery. Pediatrics*, vol. 23, no. 2, pp. 247–250, 2019.

[14] P. Sriphong, U. Limpapanasit, and S. Bhongchirawattana, “Evaluation of cefoperazone/sulbactam and vitamin K use in patients with bacterial infections,” *Thermal Science and Engineering Progress*, vol. 1, no. 1, pp. 191–193, 2019.

[15] M. Feng, S. L. Zhang, Z. J. Liang et al., “Peripheral neutrophil CD64 index combined with complement, CRP, WBC count and B cells improves the ability of diagnosing bacterial infection in SLE,” *Lupus*, vol. 28, no. 3, pp. 304–316, 2019.

[16] Y. Cai, L. Zhou, H. Wang, L. Zhang, J. Wang, and K. Zhang, “Comparison of vancomycin penetration into cerebrospinal fluid in postoperative intracranial infection and community-acquired meningitis patients,” *Journal of Clinical Pharmacy and Therapeutics*, vol. 44, no. 2, pp. 216–219, 2019.

[17] G. O’Connor, N. Krishnan, A. Fagan-Murphy et al., “Inhalable poly(lactic-co-glycolic acid)(PLGA) microparticles encapsulating all-trans-Retinoic acid (ATRA) as a host-directed, adjunctive treatment for Mycobacterium tuberculosis infection,” *European Journal of Pharmaceutics and Biopharmaceutics*, vol. 134, no. 4, pp. 153–165, 2019.

[18] M. Groznik, M. Cimerman, L. Lusa, N. R. Gorenjec, and A. Ihan, “Increased perioperative C-reactive protein and decreased postoperative albumin is associated with acute post-traumatic osteomyelitis in patients with high-energy tibial fractures,” *Injury*, vol. 50, no. 4, pp. 827–833, 2019.

[19] I. Gajic, L. Ranin, D. Kekic et al., “Tigecycline susceptibility of multidrug-resistant Acinetobacter baumannii from intensive care units in the western Balkans,” *Acta Microbiologica et Immunologica Hungarica*, vol. 67, no. 3, pp. 176–181, 2020.

[20] Y. Dong, Y. Li, Y. Zhang et al., “Cefoperazone/sulbactam therapeutic drug monitoring in patients with liver cirrhosis: potential factors affecting the pharmacokinetic/pharmacodynamic target attainment,” *Basic & Clinical Pharmacology & Toxicology*, vol. 125, no. 4, pp. 353–359, 2019.